CHICAGO -- Stereotactic body radiation contained early-stage, medically inoperable lung cancer at its site of origin in all but one patient involved in a small clinical trial reported here.     < READ MORE>

SAN FRANCISCO, Jan. 29 -- Lung cancer patients who smoke have a higher risk of dying during pulmonary resection and are more likely to develop postoperative complications, but surgery should proceed without delay, a researcher said here.     <READ MORE>

SAN FRANCISCO, Jan. 27 -- Lung cancer patients with resectable lesions had an 11% lower 5-year mortality risk when the surgery was performed by general thoracic surgeon, researchers said here.     <READ MORE>

CHICAGO, Nov. 14 -- Augmenting the standard therapy for non-small-cell lung cancer with cetuximab (Erbitux) is both safe and surprisingly effective, researchers said here.     <READ MORE>

CHICAGO, Nov. 14 -- Oncologists are still trying to figure out why the one-two combination of bevacizumab (Avastin) and erlotinib (Tarceva) leads to a punchless overall survival benefit in non-small-cell lung cancer.    <READ MORE>

CHICAGO, Nov. 17 -- The non-small-cell lung cancer tumors of African-Americans are significantly less likely to have a key mutation of the epidermal growth factor receptor (EGFR) gene, possibly affecting treatment choices.    <READ MORE>

CHCIAGO, Nov. 17 -- For carefully selected Asian patients with non-small-cell lung cancer, the tyrosine kinase inhibitor gefitinib (Iressa) significantly improved progression-free survival compared with the standard carboplatin (Paraplatin) and paclitaxel (Taxol), researchers reported here.     <READ MORE>

CHICAGO, Nov. 18 -- Non-small-cell lung cancer patients on chemotherapy who undergo treatment with proton beam radiation appear to suffer less bone marrow toxicity than those treated with conventional radiation therapy, researchers said here.    <READ MORE>

CHICAGO, Nov. 18 -- There were no differences in overall survival between non-small-cell lung cancer patients treated with erlotinib (Tarceva) alone or in combination with standard chemotherapy, researchers found.   <READ MORE>

CHICAGO, Nov. 18 -- It's two strikes against the oral multikinase inhibitor sorafenib (Nexavar) for treating advanced non-small-cell lung cancer in the ESCAPE trial.  <READ MORE>

HOBART, Australia, Oct. 9 -- Platinum-based chemotherapy for small-cell lung cancer offers no better chance of survival than other regimens and causes substantially more toxicity, according to findings of a systematic review. <READ MORE>

PASADENA, Calif., Oct. 8 -- Drinking moderate amounts of red wine may offer some protection against lung cancer in men with a history of smoking, according to a prospective cohort study.  <READ MORE>

BOSTON, Sept. 25 -- Stereotactic body radiotherapy for inoperable early-stage non-small- cell lung cancer achieved "excellent" long-term local control and "encouraging" cause-specific survival but failed to boost overall survival, according to a small Scandinavian study reported here.  <READ MORE>

Sept 23, 2008
Drug Makers Warn of Liver and Kidney Risks with EGFR-Inhibitor

ROCKVILLE, Md., Sept. 23 -- The FDA said today that the makers of the cancer drug erlotinib (Tarceva) have reported two deaths -- one from hepatorenal syndrome and one from rapidly progressing liver failure -- among patients taking the agent.    <READ MORE>

BOSTON, July 2 -- Patient response to non-small-cell lung cancer treatment can be assessed by capturing circulating tumor cells with a microchip, a small study showed.   <READ MORE>

PISA, Italy, June 18 -- Radiofrequency ablation of small lung tumors may yield outcomes that rival standard radiation for selected patients ineligible for surgery or other therapy, researchers found in a seven-center trial in Europe, the U.S., and Australia.   <READ MORE>

CHICAGO, June 6 -- In patients with advanced non-small-cell lung cancer, adding an insulin-like growth factor receptor inhibitor to chemotherapy significantly increased overall response and improved progression-free survival, according to results of a phase II study.   <READ MORE>

CHICAGO, June 5 -- Controversy and lack of evidence for a mortality benefit have made physicians reluctant to embrace spiral computed tomography (CT) screening for lung cancer.   <READ MORE>

CHICAGO, June 5 -- After primary chemotherapy, patients with advanced non-small-cell lung cancer had a significant improvement in progression-free survival with pemetrexed (Alimta) maintenance, a large multicenter study showed.   <READ MORE>

CHICAGO, June 5 -- For patients with non-small-cell lung cancer, extending their course of chemotherapy improves progression-free survival but not overall survival and at a cost of more adverse events and reduced quality of life, data from a meta-analysis suggest.   <READ MORE>

CHICAGO, June 5 -- Patients with non-small-cell lung cancer who'd already had several courses of chemotherapy had significant slowing of progression when treated with sorafenib, according to results of a small intergroup trial.  <READ MORE>

CHICAGO, June 5 -- In advanced non-small-cell lung cancer, disease progression slowed significantly when gefitinib (Iressa) was given after first-line chemotherapy, a large Japanese study showed. <READ MORE>

CHICAGO, June 5 -- Irinotecan (Camptosar) plus cisplatin (Platinol) failed to demonstrate a survival benefit in a large North American trial of patients with extensive-stage small-cell lung cancer.  <READ MORE>

CHICAGO, June 2 -- A genetic test may help determine which early stage non-small-cell lung cancer patients can be spared chemotherapy after surgery, researchers said here.  <READ MORE>

CHICAGO, June 1 -- For advanced non-small-cell lung cancer, cetuximab (Erbitux) added to platinum-based chemotherapy increased median survival by five weeks, according to an international study.  <READ MORE>

ROCHESTER, Minn., May 27 -- People with a common genetic mutation have up to twice the risk of lung cancer as do people without the variation, researchers here said.  <READ MORE>

HOUSTON, May 20 -- Long-time smokers showed significant declines in a key marker of abnormal lung cell growth after taking the anti-inflammatory drug celecoxib (Celebrex) for three months, according to interim data from a study here.  <READ MORE>

TORONTO, May 20 -- The active genes in immune cells of patients with non-small cell lung cancer are different than those of healthy patients, a researcher said here.  <READ MORE>

GENEVA, April 25 -- An immune-boosting treatment for non-small-cell lung cancer patients with completely resected stage IB or II disease is safe and well tolerated, researchers said here.  <READ MORE>

Archive 1